Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label ginisortamab trial in metastatic pancreatic ductal adenocarcinoma
2024-514129-43-00Phase 2Authorised
- Sponsor
- Cancer Research UK
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ginisortamab in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Cancer Research UK. Primary endpoints: Safety and adverse events, Recommended dose determination and 3 more. Planned start Dec 2024; status: authorised.
02
Drugs
ginisortamab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-514129-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514129-43-00.